OS analysis of patients with different short-term response and progression patterns of donafenib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: An exploratory subgroup analysis of ZGDH3
作者全名："Qin, Shukui; Bi, Feng; Xu, Jianming; Du, Chengyou; Fan, Qingxia; Zhang, Longzhen; Tao, Min; Jiang, Da; Wang, Senming; Chen, Yongping; Sheng, Jifang; Zhuang, Xuelong; Wu, Jun"
作者地址："Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China; Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China; Chiness PLA Gen Hosp, Beijing, Peoples R China; Chongqing Med Univ, Hepatobiliary Surg, Affiliated Hosp 1, Chongqing, Peoples R China; Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China; XuZhou Med Univ, Affiliated Hosp, Xuzhou, Peoples R China; Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China; Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China; Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China; WMU, Affiliated Hosp 1, Wenzhou, Peoples R China; Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China; Shantou Univ, Med Coll, Canc Hosp, Shantou, Peoples R China; First Peoples Hosp Changzhou, Changzhou, Peoples R China"
通信作者：
来源：JOURNAL OF CLINICAL ONCOLOGY
ESI学科分类：CLINICAL MEDICINE
WOS号：WOS:001053772002186
JCR分区：Q1
影响因子：42.1
年份：2023
卷号：41
期号：16
开始页：
结束页：
文献类型：Meeting Abstract
关键词：
摘要：
基金机构：
基金资助正文：
